The global molecular diagnostics in pharmacogenomics market size is anticipated to reach USD 1,256.38 million by 2033 and is expected to expand at a CAGR of 6.84% during the forecast period, according to a new report by Grand View Research, Inc. Market is driven by a convergence of technological innovation, rising demand for personalized medicine, and increasing awareness of genetic influences on drug response.

The growing recognition that pharmacogenomic testing can significantly enhance therapeutic efficacy and reduce adverse drug reactions by tailoring treatments to an individual’s genetic profile. As healthcare systems worldwide shift toward precision medicine, molecular diagnostics are becoming indispensable tools for clinicians aiming to optimize drug selection and dosage.

Advancements in genomic technologies—particularly in polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarray platforms—have dramatically improved the accuracy, speed, and affordability of molecular tests. These innovations have enabled broader clinical adoption and integration into routine care, especially in oncology, cardiology, and psychiatry, where pharmacogenomic insights are proving transformative. Moreover, the rise of point-of-care testing and liquid biopsy techniques is making molecular diagnostics more accessible, further fueling market penetration across diverse healthcare settings.

The increasing prevalence of chronic and infectious diseases also contributes to market momentum. As conditions such as cancer, diabetes, and autoimmune disorders become more widespread, the need for individualized treatment strategies intensifies. Molecular diagnostics offer a pathway to more effective disease management by identifying genetic markers that influence drug metabolism and therapeutic response. This capability not only improves patient outcomes but also reduces healthcare costs by minimizing trial-and-error prescribing and hospital readmissions.

Additionally, supportive regulatory frameworks and growing investment in genomics research are accelerating innovation and commercialization. Governments and private entities are funding initiatives to expand genetic testing infrastructure and promote clinical adoption. Strategic partnerships between diagnostic companies, pharmaceutical firms, and academic institutions are fostering the development of integrated solutions that combine diagnostics with targeted therapies.

Order a free sample PDF of the Molecular Diagnostics In Pharmacogenomics Market Intelligence Study, published by Grand View Research.

Further key findings from the report suggest:

• Based on product, the kits and assays segment led the market with the largest revenue share of 48.05% in 2024.

• Based on therapeutic area, the oncology segment led the market with the largest revenue share of 33.44% in 2024.

• Based on technology, the PCR-based segment led the market with the largest revenue share of 38.09% in 2024.

• North America dominated the market with the largest revenue share of 38.72% in 2024.

• The molecular diagnostics in pharmacogenomics market in the U.S. accounted for the largest market revenue share in North America in 2024.

List of Key Players in the Molecular Diagnostics In Pharmacogenomics Market 

• Roche Diagnostics

• QIAGEN

• Thermo Fisher Scientific

• Illumina, Inc.

• Agilent Technologies

• Abbott Molecular

• Genomind

• OneOme

• Myriad Genetics

• Invitae (formerly YouScript)

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.